{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T07:40:53Z","timestamp":1795246853962,"version":"4.10.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000380","name":"Guy's & St Thomas' Foundation","doi-asserted-by":"publisher","award":["C180209"],"award-info":[{"award-number":["C180209"]}],"id":[{"id":"10.13039\/501100000380","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06193-z","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:53:41Z","timestamp":1740041621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes"],"prefix":"10.1186","volume":"23","author":[{"given":"Federica","family":"Torricelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nedyalko","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela Terranova","family":"Barberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ciarrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-5549","authenticated-orcid":false,"given":"Benedetta","family":"Apollonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bill\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"6193_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CLEP.S105396","volume":"8","author":"JL Beebe-Dimmer","year":"2016","unstructured":"Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, Gadgeel S. Mesothelioma in the United States: a Surveillance, Epidemiology, and end results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743\u201350.","journal-title":"Clin Epidemiol"},{"issue":"14","key":"6193_CR2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"10026","key":"6193_CR3","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314.","journal-title":"Lancet"},{"issue":"10272","key":"6193_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u201386.","journal-title":"Lancet"},{"issue":"5","key":"6193_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488\u201399.","journal-title":"Ann Oncol"},{"key":"6193_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2020.09.022","volume":"150","author":"PL Chia","year":"2020","unstructured":"Chia PL, Russell P, Asadi K, Thapa B, Gebski V, Murone C, Walkiewicz M, Eriksson U, Scott AM, John T. Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. Lung Cancer. 2020;150:1\u20138.","journal-title":"Lung Cancer"},{"issue":"1","key":"6193_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 2019;10(1):1333.","journal-title":"Nat Commun"},{"issue":"4","key":"6193_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407\u201316.","journal-title":"Nat Genet"},{"key":"6193_CR9","doi-asserted-by":"crossref","unstructured":"Alay A, Cordero D, Hijazo-Pechero S, Aliagas E, Lopez-Doriga A, Marin R, Palmero R, Llatjos R, Escobar I, Ramos R et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J Immunother Cancer 2021, 9(2).","DOI":"10.1136\/jitc-2020-001601"},{"issue":"5","key":"6193_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cels.2018.02.010","volume":"6","author":"S Chevrier","year":"2018","unstructured":"Chevrier S, Crowell HL, Zanotelli VRT, Engler S, Robinson MD, Bodenmiller B. Compensation of Signal spillover in suspension and imaging Mass Cytometry. Cell Syst. 2018;6(5):612\u2013e620615.","journal-title":"Cell Syst"},{"issue":"10","key":"6193_CR11","doi-asserted-by":"publisher","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","volume":"7","author":"AE Carpenter","year":"2006","unstructured":"Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006;7(10):R100.","journal-title":"Genome Biol"},{"issue":"12","key":"6193_CR12","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41592-019-0582-9","volume":"16","author":"S Berg","year":"2019","unstructured":"Berg S, Kutra D, Kroeger T, Straehle CN, Kausler BX, Haubold C, Schiegg M, Ales J, Beier T, Rudy M, et al. Ilastik: interactive machine learning for (bio)image analysis. Nat Methods. 2019;16(12):1226\u201332.","journal-title":"Nat Methods"},{"issue":"11","key":"6193_CR13","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"issue":"4","key":"6193_CR14","first-page":"100155","volume":"2","author":"RA Belderbos","year":"2021","unstructured":"Belderbos RA, Maat A, Baart SJ, Madsen EVE, Bogers A, Cornelissen R, Aerts J, Mahtab EAF, von der Thusen JH. Ki67 (MIB-1) as a prognostic marker for clinical decision making before extended pleurectomy decortication in Malignant Pleural Mesothelioma. JTO Clin Res Rep. 2021;2(4):100155.","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"6193_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41419-023-06240-x","volume":"14","author":"Y Chrisochoidou","year":"2023","unstructured":"Chrisochoidou Y, Roy R, Farahmand P, Gonzalez G, Doig J, Krasny L, Rimmer EF, Willis AE, MacFarlane M, Huang PH, et al. Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells. Cell Death Dis. 2023;14(11):725.","journal-title":"Cell Death Dis"},{"issue":"3","key":"6193_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"31","key":"6193_CR17","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1038\/s41388-022-02406-7","volume":"41","author":"P Chen","year":"2022","unstructured":"Chen P, Dey P. Co-dependencies in the tumor immune microenvironment. Oncogene. 2022;41(31):3821\u20139.","journal-title":"Oncogene"},{"issue":"12","key":"6193_CR18","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548\u201365.","journal-title":"Cancer Discov"},{"key":"6193_CR19","doi-asserted-by":"crossref","unstructured":"Jung J, Heo YJ, Park S. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. J Immunother Cancer 2023, 11(4).","DOI":"10.1136\/jitc-2022-006454"},{"issue":"10","key":"6193_CR20","doi-asserted-by":"publisher","first-page":"e2025109","DOI":"10.1001\/jamanetworkopen.2020.25109","volume":"3","author":"C Shao","year":"2020","unstructured":"Shao C, Li G, Huang L, Pruitt S, Castellanos E, Frampton G, Carson KR, Snow T, Singal G, Fabrizio D, et al. Prevalence of High Tumor Mutational Burden and Association with Survival in patients with less common solid tumors. JAMA Netw Open. 2020;3(10):e2025109.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"6193_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jnci\/djy157","volume":"111","author":"WL Hwang","year":"2019","unstructured":"Hwang WL, Wolfson RL, Niemierko A, Marcus KJ, DuBois SG, Haas-Kogan D. Clinical impact of Tumor Mutational Burden in Neuroblastoma. J Natl Cancer Inst. 2019;111(7):695\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"6193_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jtho.2018.04.003","volume":"13","author":"Y Owada-Ozaki","year":"2018","unstructured":"Owada-Ozaki Y, Muto S, Takagi H, Inoue T, Watanabe Y, Fukuhara M, Yamaura T, Okabe N, Matsumura Y, Hasegawa T, et al. Prognostic impact of Tumor Mutation Burden in patients with completely resected Non-small Cell Lung Cancer: brief report. J Thorac Oncol. 2018;13(8):1217\u201321.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"6193_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","volume":"53","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Wang J, Nadeem Z, Patel N, Postow MA, Shoushtari AN, Plitas G, Balachandran VP, et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat Genet. 2021;53(1):11\u20135.","journal-title":"Nat Genet"},{"issue":"1","key":"6193_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","volume":"6","author":"S Maleki Vareki","year":"2018","unstructured":"Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157.","journal-title":"J Immunother Cancer"},{"issue":"6280","key":"6193_CR25","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science"},{"issue":"13","key":"6193_CR26","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385(13):1207\u201318.","journal-title":"N Engl J Med"},{"issue":"3","key":"6193_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"1","key":"6193_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of Cancer: New dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"10","key":"6193_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","volume":"25","author":"P Courtiol","year":"2019","unstructured":"Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N, et al. Deep learning-based classification of mesothelioma improves prediction of patient outcome. Nat Med. 2019;25(10):1519\u201325.","journal-title":"Nat Med"},{"issue":"1","key":"6193_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-023-01816-9","volume":"22","author":"F Torricelli","year":"2023","unstructured":"Torricelli F, Donati B, Reggiani F, Manicardi V, Piana S, Valli R, Lococo F, Ciarrocchi A. Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy. Mol Cancer. 2023;22(1):114.","journal-title":"Mol Cancer"},{"issue":"11","key":"6193_CR31","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","volume":"14","author":"B Giotti","year":"2024","unstructured":"Giotti B, Dolasia K, Zhao W, Cai P, Sweeney R, Merritt E, Kiner E, Kim GS, Bhagwat A, Nguyen T, et al. Single-cell view of Tumor Microenvironment gradients in Pleural Mesothelioma. Cancer Discov. 2024;14(11):2262\u201378.","journal-title":"Cancer Discov"},{"issue":"3","key":"6193_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41416-020-01130-x","volume":"124","author":"MG White","year":"2021","unstructured":"White MG, Schulte JJ, Xue L, Berger Y, Schuitevoerder D, Vining CC, Kindler HL, Husain A, Turaga KK, Eng OS. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 2021;124(3):564\u20136.","journal-title":"Br J Cancer"},{"issue":"5","key":"6193_CR33","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jtho.2017.03.018","volume":"12","author":"S Lantuejoul","year":"2017","unstructured":"Lantuejoul S, Le Stang N, Damiola F, Scherpereel A, Galateau-Salle F. PD-L1 testing for Immune checkpoint inhibitors in Mesothelioma: for want of anything better? J Thorac Oncol. 2017;12(5):778\u201381.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"6193_CR34","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","volume":"29","author":"G Pasello","year":"2018","unstructured":"Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol. 2018;29(5):1258\u201365.","journal-title":"Ann Oncol"},{"issue":"5","key":"6193_CR35","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","volume":"12","author":"B Thapa","year":"2017","unstructured":"Thapa B, Salcedo A, Lin X, Walkiewicz M, Murone C, Ameratunga M, Asadi K, Deb S, Barnett SA, Knight S, et al. The Immune Microenvironment, Genome-wide Copy Number aberrations, and Survival in Mesothelioma. J Thorac Oncol. 2017;12(5):850\u20139.","journal-title":"J Thorac Oncol"},{"key":"6193_CR36","doi-asserted-by":"crossref","unstructured":"Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti D et al. Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types. J Immunol Res 2018;2018:5804230.","DOI":"10.1155\/2018\/5804230"},{"issue":"6","key":"6193_CR37","doi-asserted-by":"publisher","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","volume":"4","author":"H Ujiie","year":"2015","unstructured":"Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, Travis WD, Jones DR, Krug LM, Adusumilli PS. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers. Oncoimmunology. 2015;4(6):e1009285.","journal-title":"Oncoimmunology"},{"key":"6193_CR38","doi-asserted-by":"crossref","unstructured":"Lee HS, Jang HJ, Choi JM, Zhang J, de Rosen VL, Wheeler TM, Lee JS, Tu T, Jindra PT, Kerman RH et al. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight 2018, 3(7).","DOI":"10.1172\/jci.insight.98575"},{"issue":"8","key":"6193_CR39","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","volume":"14","author":"IC Salaroglio","year":"2019","unstructured":"Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, et al. Potential diagnostic and prognostic role of Microenvironment in Malignant Pleural Mesothelioma. J Thorac Oncol. 2019;14(8):1458\u201371.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"6193_CR40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41590-021-00949-7","volume":"22","author":"JL Collier","year":"2021","unstructured":"Collier JL, Weiss SA, Pauken KE, Sen DR, Sharpe AH. Not-so-opposite ends of the spectrum: CD8(+) T cell dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol. 2021;22(7):809\u201319.","journal-title":"Nat Immunol"},{"key":"6193_CR41","doi-asserted-by":"crossref","unstructured":"Harber J, Kamata T, Pritchard C, Fennell D. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. J Immunother Cancer 2021, 9(9).","DOI":"10.1136\/jitc-2021-003032"},{"key":"6193_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41021-019-0129-4","volume":"41","author":"T Ishida","year":"2019","unstructured":"Ishida T, Fujihara N, Nishimura T, Funabashi H, Hirota R, Ikeda T, Kuroda A. Live-cell imaging of macrophage phagocytosis of asbestos fibers under fluorescence microscopy. Genes Environ. 2019;41:14.","journal-title":"Genes Environ"},{"issue":"8","key":"6193_CR43","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA. The complex role of tumor-infiltrating macrophages. Nat Immunol. 2022;23(8):1148\u201356.","journal-title":"Nat Immunol"},{"issue":"9","key":"6193_CR44","doi-asserted-by":"publisher","first-page":"e2210836120","DOI":"10.1073\/pnas.2210836120","volume":"120","author":"L Wu","year":"2023","unstructured":"Wu L, Kohno M, Murakami J, Zia A, Allen J, Yun H, Chan M, Baciu C, Liu M, Serre-Beinier V, et al. Defining and targeting tumor-associated macrophages in malignant mesothelioma. Proc Natl Acad Sci U S A. 2023;120(9):e2210836120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"6193_CR45","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","volume":"85","author":"JG Edwards","year":"2001","unstructured":"Edwards JG, Cox G, Andi A, Jones JL, Walker RA, Waller DA, O\u2019Byrne KJ. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer. 2001;85(6):863\u20138.","journal-title":"Br J Cancer"},{"issue":"5","key":"6193_CR46","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1378\/chest.124.5.1916","volume":"124","author":"JG Edwards","year":"2003","unstructured":"Edwards JG, Swinson DE, Jones JL, Muller S, Waller DA, O\u2019Byrne KJ. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest. 2003;124(5):1916\u201323.","journal-title":"Chest"},{"issue":"2","key":"6193_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.seminoncol.2019.06.001","volume":"46","author":"A Tsao","year":"2019","unstructured":"Tsao A, Nakano T, Nowak AK, Popat S, Scagliotti GV, Heymach J. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Semin Oncol. 2019;46(2):145\u201354.","journal-title":"Semin Oncol"},{"issue":"10","key":"6193_CR48","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","volume":"22","author":"C Pinto","year":"2021","unstructured":"Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021;22(10):1438\u201347.","journal-title":"Lancet Oncol"},{"issue":"1","key":"6193_CR49","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang M, Luo JL, Sun Q, Harber J, Dawson AG, Nakas A, Busacca S, Sharkey AJ, Waller D, Sheaff MT, et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat Commun. 2021;12(1):1751.","journal-title":"Nat Commun"},{"issue":"2","key":"6193_CR50","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","volume":"29","author":"N Niknafs","year":"2023","unstructured":"Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat Med. 2023;29(2):440\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"6193_CR51","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1038\/s41598-023-31579-8","volume":"13","author":"T Imamura","year":"2023","unstructured":"Imamura T, Ashida R, Ohshima K, Uesaka K, Sugiura T, Ohgi K, Yamada M, Otsuka S, Hatakeyama K, Nagashima T, et al. Characterization of pancreatic cancer with ultra-low tumor mutational burden. Sci Rep. 2023;13(1):4359.","journal-title":"Sci Rep"},{"key":"6193_CR52","doi-asserted-by":"crossref","unstructured":"Zheng M. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. J Immunother Cancer 2022, 10(1).","DOI":"10.1136\/jitc-2021-003087"},{"issue":"2","key":"6193_CR53","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","volume":"14","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, et al. Neoantigenic potential of Complex chromosomal rearrangements in Mesothelioma. J Thorac Oncol. 2019;14(2):276\u201387.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"6193_CR54","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021;12(1):5606.","journal-title":"Nat Commun"},{"issue":"5","key":"6193_CR55","first-page":"100672","volume":"5","author":"D Xu","year":"2024","unstructured":"Xu D, Gao Y, Yang H, Spils M, Marti TM, Losmanova T, Su M, Wang W, Zhou Q, Dorn P, et al. BAP1 Deficiency inflames the Tumor Immune Microenvironment and is a candidate biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma. JTO Clin Res Rep. 2024;5(5):100672.","journal-title":"JTO Clin Res Rep"},{"issue":"4","key":"6193_CR56","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1158\/2159-8290.CD-22-1015","volume":"13","author":"M Pourmaleki","year":"2023","unstructured":"Pourmaleki M, Socci ND, Hollmann TJ, Mellinghoff IK. Moving spatially resolved multiplexed protein profiling toward clinical oncology. Cancer Discov. 2023;13(4):824\u20138.","journal-title":"Cancer Discov"},{"issue":"1","key":"6193_CR57","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/s12967-022-03813-w","volume":"20","author":"M Liu","year":"2022","unstructured":"Liu M, Liu L, Song Y, Li W, Xu L. Targeting macrophages: a novel treatment strategy in solid tumors. J Transl Med. 2022;20(1):586.","journal-title":"J Transl Med"},{"key":"6193_CR58","doi-asserted-by":"crossref","unstructured":"Magkouta SF, Vaitsi PC, Pappas AG, Iliopoulou M, Kosti CN, Psarra K, Kalomenidis IT. CSF1\/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy. Cancers (Basel) 2021, 13(11).","DOI":"10.3390\/cancers13112546"},{"key":"6193_CR59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/EDBK_237987","volume":"39","author":"M Datta","year":"2019","unstructured":"Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book. 2019;39:165\u201374.","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06193-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:53:45Z","timestamp":1740041625000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06193-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6193"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06193-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read the manuscript and provided their consent for the submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.B. is a consultant for Intuitive Surgical. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors affiliated to the IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Bari are responsible for the views expressed in this article which do not necessarily represent the Institute.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"208"}}